Acadia Pharmaceuticals | ACAD - Interest Income


Acadia Pharmaceuticals reported $8.33M in Interest Income for its fiscal quarter ending in December of 2025.





Interest Income Change Date
Acadia Pharmaceuticals USD 8.33M 86K Dec/2025
ALKERMES USD 8.54M 3.59M Mar/2026
Alnylam Pharmaceuticals USD 26.63M 2.05M Dec/2025
Biogen USD 37.9M 700K Mar/2026
BioMarin Pharmaceutical USD 22.56M 3.35M Mar/2026
Cara Therapeutics USD 347K 74K Mar/2025
Corcept Therapeutics USD 5.42M 399K Dec/2025
Cytokinetics USD 11.02M 448K Mar/2026
Eisai JPY 3.11B 783M Mar/2024
Eli Lilly USD 65M 25M Sep/2025
Incyte USD 33.69M 2.93M Mar/2026
J&J USD 2.14 237M Mar/2026
Moderna USD 70M 3M Dec/2025
Pfizer USD 115M 51M Mar/2026
Prothena USD 2.42M 935K Mar/2026
Sarepta Therapeutics USD 8.74M 359K Dec/2025
Ultragenyx Pharmaceutical USD 6.51M 649K Dec/2025
Vertex Pharmaceuticals USD 114.8M 7.1M Mar/2026